Wednesday, December 18, 2013

Frosty Future for Erectile Dysfunction Drugs

A recent report published by Transparency Market Research has cast a pall on the future profitability of the PDE5 inhibitor sex drug class, forecasting that annual sales of sexual dysfunction drugs will fall from $4.3 billion in 2012 to $3.4 billion in 2019. The study authors opine that the loss of Pfizer’s (PFE) Viagra patent exclusivity in Canada, Asia and Europe will weaken all drug manufacturers’ lock – including Eli Lilly’s (LLY) Cialis and Bayer’s (BAYRY) Levitra – on pricing power in coming years.

Though a U.S. federal judge reaffirmed Pfizer’s “method-of-use” patent, blocking Teva Pharmaceuticals (TEVA) and others from launching their own generic versions until October 2019, the competitive landscape elsewhere is more hostile. Through September 2013, Pfizer reported that U.S. sales of Viagra held steady at $819 million; international revenue declined 13% to $586 million, however, as the Israeli-based drug maker, U.S.-based generic manufacturers Actavis (ACT) and Mylan (MYL), and other generic houses started to roll-out cheaper copies of sildenafil back in July.

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy. 

1 comment:

Mike Allison said...

This post is very important for Erectile Dysfunction treatment. I like this ...